Hub : Traits :

Bipolar Disorder or Schizophrenia

972 significantly associated models · 245 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	43476957	45088053	1	1	2.5e-07	8.7e-10	1.4e-04	61	ST3GAL3
2	1	149672809	151435941	7	1	3.5e-11	1.0e-11	1.0e+00	100	PLEKHO1
3	1	154219485	155625602	1	1	2.1e-07	4.4e-07	3.4e-01	96	PBXIP1
4	1	242590540	244359621	3	1	1.1e-10	7.0e-09	2.2e-03	72	CEP170
5	2	26635328	28038799	1	1	8.2e-08	2.6e-08	1.1e-05	38	CGREF1
6	2	73005579	74383630	1	1	1.7e-07	5.6e-08	9.8e-02	91	ALMS1-IT1
7	2	96669134	98622697	4	2	4.4e-11	1.7e-10	1.0e+00	100	LMAN2L TMEM127
8	2	197134790	199259516	5	2	1.6e-11	6.6e-11	1.1e-01	94	ANKRD44 HSPD1
9	2	200086752	202078494	4	1	1.7e-13	7.3e-13	9.5e-02	95	C2orf47
10	2	207747657	209182548	2	1	1.2e-07	1.8e-07	1.0e+00	100	METTL21A
11	2	224636490	226142508	1	1	1.5e-07	2.2e-06	2.1e-01	93	CUL3
12	2	233227833	234123010	3	2	2.3e-10	1.8e-11	1.0e+00	100	EFHD1 NGEF
13	3	1442951	3792945	1	1	5.1e-10	2.4e-12	9.8e-06	60	CNTN4
14	3	36176466	37914922	3	1	1.1e-13	1.0e-18	7.7e-12	40	LRRFIP2
15	3	51616334	54077726	18	1	4.8e-15	3.8e-13	2.3e-01	97	ITIH4-AS1
16	3	63121945	64546545	1	1	2.2e-09	5.0e-09	3.1e-01	97	THOC7
17	3	132509832	133350222	1	1	2.3e-07	9.3e-07	2.6e-01	95	TMEM108
18	5	44129083	45516364	2	1	6.9e-08	1.2e-08	2.6e-02	85	RP11-53O19.3
19	5	59474215	60936935	1	1	9.5e-09	2.3e-11	1.9e-04	69	ERCC8
20	5	136972187	138474788	3	1	1.4e-12	2.7e-10	2.4e-01	97	FAM53C
21	5	139232299	141087689	9	1	7.2e-09	2.0e-07	4.6e-01	98	IK
22	6	24300846	24891985	1	1	1.1e-07	3.2e-05	8.0e-02	82	KIAA0319
23	6	25285943	26689223	2	2	7.5e-12	1.3e-21	1.3e-08	65	TRIM38 U91328.21
24	6	42946943	43582584	2	2	7.1e-09	9.5e-08	1.0e+00	100	C6orf108 ZNF318
25	6	83228260	84829622	2	1	4.4e-13	3.1e-12	4.0e-01	99	SNAP91
26	7	1161158	2977732	2	1	9.3e-10	1.1e-12	1.5e-04	72	FTSJ2
27	7	20767954	22254276	1	1	2.4e-07	7.2e-07	2.3e-01	94	SP4
28	7	24040297	25508637	1	1	1.9e-08	1.1e-10	1.4e-03	76	DFNA5
29	7	86535446	87065687	1	1	1.4e-07	2.3e-07	1.1e-01	90	DMTF1
30	8	25544268	26938804	1	1	1.1e-07	5.1e-08	1.0e+00	100	SDAD1P1
31	8	37329315	38932193	7	1	4.5e-11	8.4e-09	2.7e-01	96	PPAPDC1B
32	8	142839492	144323692	2	1	6.6e-08	1.2e-11	1.1e-06	48	BAI1
33	10	101744428	102275727	1	1	2.2e-07	2.3e-05	7.5e-01	99	CWF19L1
34	10	103313599	105647095	14	1	8.5e-19	6.0e-16	4.9e-01	99	AS3MT
35	11	62922117	64707978	3	1	2.0e-14	3.1e-09	3.8e-02	88	PPP1R14B
36	11	65405300	67324933	11	1	7.0e-10	2.9e-09	7.4e-01	100	CTD-3074O7.5
37	12	1204676	2805632	2	2	5.5e-17	3.3e-20	1.5e-04	83	CACNA2D4 DCP1B
38	12	122713991	124591385	10	1	2.7e-10	4.8e-10	1.0e+00	100	CDK2AP1
39	14	71126913	71826787	1	1	2.9e-07	1.7e-06	8.9e-01	100	PCNX
40	14	103161201	105211221	12	1	3.4e-13	2.3e-12	1.4e-01	96	PPP1R13B
41	15	78135979	79537269	2	1	7.5e-12	1.8e-11	1.0e+00	100	CHRNA5
42	15	83167559	83804861	2	1	7.0e-09	9.5e-08	6.8e-01	99	CPEB1
43	15	84151637	86489699	13	1	3.3e-15	1.8e-14	2.9e-01	98	AC103965.1
44	15	90718541	92135418	3	1	4.9e-15	2.5e-13	4.1e-02	92	FES
45	16	28825605	31026427	17	1	2.7e-11	6.8e-11	6.1e-02	92	MAPK3
46	16	57850605	59241430	1	1	3.8e-08	2.7e-08	1.2e-01	92	SETD6
47	16	67351698	70136868	4	2	2.9e-08	2.3e-07	2.3e-01	95	DUS2 TERF2
48	16	73971308	75396376	1	1	2.3e-07	5.0e-06	1.6e-02	72	RFWD3
49	16	88858246	90172696	4	1	3.1e-08	1.4e-06	1.9e-02	76	SPATA33
50	17	12647408	13160648	1	1	1.5e-07	1.8e-06	7.0e-01	99	ELAC2
51	17	18051975	20017091	6	2	2.8e-09	2.1e-07	2.2e-01	94	GRAP PRPSAP2
52	19	18408222	20451172	12	2	2.6e-11	7.1e-10	6.8e-01	100	LPAR2 SUGP2
53	20	36681910	38094711	1	1	2.5e-09	2.6e-10	7.7e-04	72	ACTR5
54	20	42924921	44408428	1	1	2.6e-09	2.4e-09	1.0e+00	100	STK4
55	20	49333081	49817847	1	1	2.5e-07	2.2e-08	9.7e-03	79	MOCS3
56	22	21798199	23032448	4	1	1.6e-09	3.7e-08	9.5e-01	100	LL22NC03-86G7.1
57	22	39192995	43232818	15	3	1.0e-11	1.6e-10	2.6e-04	67	MGAT3 NAGA XPNPEP3

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Schizophrenia (2018)	13.28	61	29	64.4	0.99	4.4e-51	AC103965.1 ACTR5 ALMS1-IT1 ANKRD44 AS3MT BAI1 C2orf47 C6orf108 CACNA2D4 CDK2AP1 CEP170 CGREF1 CHRNA5 CNTN4 CPEB1 CTD-3074O7.5 CUL3 CWF19L1 DCP1B DMTF1 DUS2 EFHD1 ELAC2 ERCC8 FAM53C FES FTSJ2 GRAP HSPD1 IK ITIH4-AS1 KIAA0319 LMAN2L LPAR2 LRRFIP2 MAPK3 METTL21A MGAT3 NAGA NGEF PCNX PLEKHO1 PPAPDC1B PPP1R13B PPP1R14B PRPSAP2 RFWD3 RP11-53O19.3 SDAD1P1 SETD6 SNAP91 SP4 ST3GAL3 SUGP2 TERF2 THOC7 TMEM127 TRIM38 U91328.21 XPNPEP3 ZNF318
Schizophrenia (2014)	13.10	60	33	73.3	0.99	1.3e-51	AC103965.1 ACTR5 ALMS1-IT1 ANKRD44 AS3MT BAI1 C2orf47 C6orf108 CACNA2D4 CDK2AP1 CEP170 CGREF1 CHRNA5 CNTN4 CPEB1 CUL3 CWF19L1 DCP1B DMTF1 DUS2 EFHD1 ELAC2 ERCC8 FAM53C FES FTSJ2 GRAP HSPD1 IK ITIH4-AS1 KIAA0319 LL22NC03-86G7.1 LMAN2L LPAR2 LRRFIP2 MAPK3 METTL21A MGAT3 MOCS3 NAGA NGEF PBXIP1 PCNX PLEKHO1 PPAPDC1B PPP1R13B PPP1R14B PRPSAP2 RFWD3 RP11-53O19.3 SETD6 SNAP91 SPATA33 ST3GAL3 STK4 SUGP2 THOC7 TMEM127 XPNPEP3 ZNF318
Bipolar Disorder (2018)	8.10	19	7	15.6	1.00	1.0e-18	AC103965.1 CACNA2D4 CTD-3074O7.5 DFNA5 ITIH4-AS1 LL22NC03-86G7.1 LMAN2L LPAR2 LRRFIP2 MAPK3 PLEKHO1 PPAPDC1B PPP1R14B PRPSAP2 SNAP91 SPATA33 STK4 SUGP2 XPNPEP3
Tanning	7.35	3	1	2.2	0.00	1.0e+00	ERCC8 ITIH4-AS1 SPATA33
Hair Pigment	6.64	10	7	15.6	-0.27	4.5e-01	CDK2AP1 CPEB1 EFHD1 FAM53C FES PCNX PLEKHO1 PPP1R13B SPATA33 XPNPEP3
Bipolar Disorder (2011)	6.55	5	0	0.0	0.99	1.0e-03	CACNA2D4 CTD-3074O7.5 ITIH4-AS1 LMAN2L SNAP91
Pack years adult smoking proportion	3.65	2	1	2.2	0.00	1.0e+00	CHRNA5 PPP1R13B
Pack years of smoking	3.29	1	1	2.2	0.00	1.0e+00	CHRNA5
Risk taking	2.89	2	1	2.2	0.00	1.0e+00	CEP170 PPP1R13B
Breast Cancer	2.78	5	2	4.4	-0.90	3.7e-02	C6orf108 FES LPAR2 RP11-53O19.3 SUGP2
Verbal and Numeric Reasoning (VNR)	2.69	8	2	4.4	-0.76	2.7e-02	ALMS1-IT1 CDK2AP1 IK ITIH4-AS1 MGAT3 NAGA ST3GAL3 U91328.21
Impedance of leg (right)	2.69	12	10	22.2	0.10	7.6e-01	AC103965.1 AS3MT C2orf47 CTD-3074O7.5 ERCC8 FES ITIH4-AS1 MAPK3 PBXIP1 PPAPDC1B PPP1R13B SUGP2
Impedance of leg (left)	2.59	12	10	22.2	-0.01	9.8e-01	AC103965.1 AS3MT CDK2AP1 CTD-3074O7.5 ERCC8 FES ITIH4-AS1 MAPK3 PBXIP1 PPAPDC1B PPP1R13B SUGP2
Diastolic blood pressure, automated reading	2.58	6	5	11.1	-0.58	2.2e-01	ALMS1-IT1 CDK2AP1 CEP170 FES TMEM127 U91328.21
Impedance of whole body	2.58	14	11	24.4	0.35	2.2e-01	AC103965.1 ANKRD44 AS3MT CTD-3074O7.5 ERCC8 FTSJ2 HSPD1 ITIH4-AS1 LPAR2 MAPK3 PBXIP1 PPAPDC1B PPP1R13B SUGP2
Intelligence (Savage-Jansen 2018)	2.48	8	4	8.9	-0.74	3.6e-02	ALMS1-IT1 C6orf108 CDK2AP1 CWF19L1 IK ITIH4-AS1 MGAT3 ST3GAL3
Qualifications: College or University degree	2.47	8	5	11.1	0.01	9.9e-01	ALMS1-IT1 CDK2AP1 DFNA5 ERCC8 MGAT3 SDAD1P1 ST3GAL3 STK4
Vascular/heart problems diagnosed by doctor	2.44	3	1	2.2	0.00	1.0e+00	FES PCNX SPATA33
Systolic Blood Pressure	2.43	8	7	15.6	-0.23	5.9e-01	AS3MT C2orf47 DFNA5 FES IK PCNX PPAPDC1B PPP1R14B
Number of incorrect matches in round	2.40	4	1	2.2	-0.29	7.1e-01	AS3MT C6orf108 FES MAPK3
Fluid intelligence score	2.35	6	2	4.4	-0.66	1.5e-01	ALMS1-IT1 CDK2AP1 CGREF1 MGAT3 ST3GAL3 U91328.21
High blood pressure (mother)	2.34	1	1	2.2	0.00	1.0e+00	FES
Hypertension (Self-reported)	2.33	3	2	4.4	0.00	1.0e+00	FES PPP1R14B SPATA33
High blood pressure	2.32	3	1	2.2	0.00	1.0e+00	FES PCNX SPATA33
Worrier / anxious feelings	2.32	4	2	4.4	0.99	1.2e-02	AS3MT C2orf47 CACNA2D4 ITIH4-AS1
Smoking Status	2.31	6	3	6.7	0.24	6.5e-01	AS3MT ERCC8 FES PPP1R13B SNAP91 ST3GAL3
Illnesses of father: High blood pressure	2.29	1	1	2.2	0.00	1.0e+00	FES
Worry (Nagel 2018)	2.22	5	2	4.4	0.99	1.4e-03	AS3MT C2orf47 ITIH4-AS1 SUGP2 XPNPEP3
Qualifications: A levels/AS levels or equivalent	2.22	5	2	4.4	-0.27	6.7e-01	CDK2AP1 DFNA5 ERCC8 MGAT3 ST3GAL3
Medication: Paracetamol	2.20	1	1	2.2	0.00	1.0e+00	U91328.21
Impedance of arm (left)	2.19	12	6	13.3	0.54	7.1e-02	AC103965.1 ANKRD44 CGREF1 ERCC8 HSPD1 ITIH4-AS1 LPAR2 MAPK3 PPAPDC1B PRPSAP2 SNAP91 SUGP2
Impedance of arm (right)	2.18	12	6	13.3	0.56	5.8e-02	AC103965.1 ANKRD44 ERCC8 FAM53C HSPD1 ITIH4-AS1 LPAR2 MAPK3 PBXIP1 PPAPDC1B SNAP91 SUGP2
Current tobacco smoking	2.13	6	0	0.0	0.50	3.1e-01	AS3MT CHRNA5 CUL3 METTL21A PPP1R13B ST3GAL3
Medication for pain relief, constipation, heartburn	2.11	3	1	2.2	0.00	1.0e+00	CDK2AP1 PCNX U91328.21
Medication: Blood pressure	2.11	1	1	2.2	0.00	1.0e+00	FES
Smoking status: Current	2.11	5	1	2.2	0.44	4.6e-01	AS3MT CUL3 METTL21A PPP1R13B ST3GAL3
Seen doctor (GP) for nerves, anxiety, tension or depression	2.09	2	0	0.0	0.00	1.0e+00	CTD-3074O7.5 U91328.21
Qualifications: None of the above	2.05	4	3	6.7	0.43	5.7e-01	CDK2AP1 DFNA5 ERCC8 ST3GAL3
Qualifications: O levels/GCSEs or equivalent	2.05	2	1	2.2	0.00	1.0e+00	CDK2AP1 DFNA5
Systolic blood pressure, automated reading	2.04	4	2	4.4	-0.34	6.6e-01	AS3MT FES PPAPDC1B PPP1R14B
Medication: Paracetamol	2.01	1	0	0.0	0.00	1.0e+00	U91328.21
Cardiovascular Disease	1.99	4	2	4.4	-0.20	8.0e-01	AS3MT FES PCNX PPP1R13B
Medication for cholesterol, blood pressure or diabetes	1.99	1	1	2.2	0.00	1.0e+00	FES
Maternal smoking around birth	1.96	3	1	2.2	0.00	1.0e+00	AS3MT CHRNA5 PPP1R13B
Leg predicted mass (right)	1.96	12	5	11.1	-0.33	3.0e-01	AS3MT C2orf47 CDK2AP1 CEP170 EFHD1 ERCC8 FES MAPK3 METTL21A MGAT3 PBXIP1 PPAPDC1B
Leg fat-free mass (right)	1.95	13	5	11.1	-0.35	2.4e-01	AS3MT C2orf47 CDK2AP1 CEP170 EFHD1 ERCC8 FES MAPK3 METTL21A MGAT3 PBXIP1 PPAPDC1B STK4
Arm fat-free mass (right)	1.94	11	5	11.1	-0.40	2.2e-01	AS3MT CDK2AP1 EFHD1 ERCC8 FAM53C HSPD1 MAPK3 METTL21A MGAT3 PBXIP1 PPAPDC1B
Ever smoked	1.94	2	0	0.0	0.00	1.0e+00	AS3MT CDK2AP1
Chronotype (morning person)	1.93	2	2	4.4	0.00	1.0e+00	CTD-3074O7.5 TMEM108
Arm fat-free mass (left)	1.93	10	4	8.9	-0.40	2.5e-01	AS3MT CDK2AP1 EFHD1 ERCC8 FTSJ2 HSPD1 MAPK3 METTL21A MGAT3 PPAPDC1B
Waist Hip Ratio (WHR)	1.92	10	2	4.4	-0.01	9.9e-01	AC103965.1 C6orf108 CDK2AP1 CGREF1 DUS2 ERCC8 FAM53C ITIH4-AS1 MGAT3 PCNX
Leg predicted mass (left)	1.92	11	5	11.1	-0.31	3.6e-01	AS3MT C2orf47 CDK2AP1 EFHD1 ERCC8 FES MAPK3 METTL21A MGAT3 PBXIP1 PPAPDC1B
Whole body water mass	1.92	10	6	13.3	-0.36	3.0e-01	AS3MT CDK2AP1 CEP170 EFHD1 ERCC8 MAPK3 METTL21A MGAT3 PBXIP1 PPAPDC1B
Leg fat-free mass (left)	1.91	11	5	11.1	-0.31	3.6e-01	AS3MT C2orf47 CDK2AP1 EFHD1 ERCC8 FES MAPK3 METTL21A MGAT3 PBXIP1 PPAPDC1B
Alcohol usually taken with meals	1.90	1	0	0.0	0.00	1.0e+00	FES
Whole body fat-free mass	1.90	9	5	11.1	-0.35	3.6e-01	AS3MT CDK2AP1 EFHD1 ERCC8 MAPK3 METTL21A MGAT3 PBXIP1 PPAPDC1B
Arm predicted mass (right)	1.89	10	4	8.9	-0.40	2.5e-01	AS3MT CDK2AP1 EFHD1 ERCC8 HSPD1 MAPK3 METTL21A MGAT3 PBXIP1 PPAPDC1B
Basal metabolic rate	1.89	12	4	8.9	-0.46	1.3e-01	AS3MT C2orf47 CDK2AP1 CEP170 EFHD1 ERCC8 IK MAPK3 METTL21A MGAT3 PBXIP1 PPAPDC1B
Arm predicted mass (left)	1.89	9	4	8.9	-0.33	3.9e-01	AS3MT CDK2AP1 EFHD1 ERCC8 HSPD1 MAPK3 METTL21A MGAT3 PPAPDC1B
Nervous feelings	1.85	2	2	4.4	0.00	1.0e+00	AS3MT ITIH4-AS1
Mouth/teeth dental problems: Dentures	1.83	2	0	0.0	0.00	1.0e+00	CHRNA5 TRIM38
Illnesses of father: Heart disease	1.82	1	1	2.2	0.00	1.0e+00	FES
Trunk fat-free mass	1.80	11	6	13.3	-0.36	2.7e-01	AS3MT CDK2AP1 EFHD1 ERCC8 FAM53C HSPD1 MAPK3 METTL21A MGAT3 PBXIP1 PPAPDC1B
Trunk predicted mass	1.80	10	6	13.3	-0.35	3.3e-01	AS3MT CDK2AP1 EFHD1 ERCC8 HSPD1 MAPK3 METTL21A MGAT3 PBXIP1 PPAPDC1B
Multivitamins +/- minerals	1.77	1	0	0.0	0.00	1.0e+00	BAI1
Comparative body size at age 10	1.77	7	0	0.0	-0.99	3.4e-05	C6orf108 ERCC8 LL22NC03-86G7.1 LPAR2 MAPK3 SUGP2 U91328.21
Qualifications: nursing, teaching	1.77	2	1	2.2	0.00	1.0e+00	CDK2AP1 ERCC8
Tense / 'highly strung'	1.75	1	0	0.0	0.00	1.0e+00	CACNA2D4
Medication: Blood pressure	1.75	2	1	2.2	0.00	1.0e+00	FES SPATA33
Prostate Cancer	1.74	1	0	0.0	0.00	1.0e+00	PBXIP1
Illnesses of father: None of the above (group 1)	1.74	1	1	2.2	0.00	1.0e+00	FES
Weight	1.73	7	3	6.7	-0.44	3.2e-01	AC103965.1 AS3MT C2orf47 CDK2AP1 EFHD1 MAPK3 TRIM38
Lung cancer (father)	1.71	1	1	2.2	0.00	1.0e+00	CHRNA5
Past tobacco smoking	1.70	1	1	2.2	0.00	1.0e+00	AS3MT
Birth weight of first child	1.70	2	1	2.2	0.00	1.0e+00	AS3MT FES
Birth weight	1.70	3	1	2.2	0.00	1.0e+00	AS3MT DUS2 FES
Frequency of tiredness / lethargy in last 2 weeks	1.69	1	0	0.0	0.00	1.0e+00	PPP1R13B
Neuroticism (Nagel 2018)	1.68	3	0	0.0	0.00	1.0e+00	AS3MT SP4 SUGP2
BMI	1.68	9	5	11.1	-0.60	8.6e-02	AS3MT BAI1 C2orf47 CTD-3074O7.5 ITIH4-AS1 MAPK3 METTL21A PBXIP1 PPP1R13B
Forced expiratory volume in 1-second (FEV1), predicted percentage	1.68	3	2	4.4	0.00	1.0e+00	CHRNA5 PLEKHO1 U91328.21
Fasting Glucose	1.67	1	1	2.2	0.00	1.0e+00	CGREF1
Sitting height	1.67	12	7	15.6	0.01	9.7e-01	AC103965.1 CDK2AP1 EFHD1 FAM53C IK LPAR2 MGAT3 NGEF SUGP2 TERF2 THOC7 TRIM38
Chronic bronchitis/emphysema (father)	1.67	1	1	2.2	0.00	1.0e+00	CHRNA5
Headache pain in last month	1.67	2	2	4.4	0.00	1.0e+00	CEP170 U91328.21
Medication: Ramipril	1.65	1	0	0.0	0.00	1.0e+00	FES
Medication: Simvastatin	1.65	1	1	2.2	0.00	1.0e+00	FES
Allergy or Eczema	1.64	3	2	4.4	0.00	1.0e+00	ANKRD44 CDK2AP1 HSPD1
Waist circumference	1.64	5	1	2.2	-0.70	1.9e-01	AS3MT BAI1 C2orf47 MAPK3 PPP1R13B
Hip circumference	1.64	7	2	4.4	-0.52	2.3e-01	AC103965.1 AS3MT BAI1 CDK2AP1 EFHD1 ITIH4-AS1 MAPK3
Guilty feelings	1.62	1	0	0.0	0.00	1.0e+00	KIAA0319
Asthma	1.61	2	0	0.0	0.00	1.0e+00	SPATA33 U91328.21
Comparative height size at age 10	1.61	9	5	11.1	0.28	4.6e-01	AC103965.1 CDK2AP1 EFHD1 FES ITIH4-AS1 LL22NC03-86G7.1 MAPK3 ST3GAL3 U91328.21
Depressed Affect (Nagel 2018)	1.60	1	0	0.0	0.00	1.0e+00	STK4
Illnesses of mother	1.60	1	1	2.2	0.00	1.0e+00	FES
Asthma (self-reported)	1.60	2	0	0.0	0.00	1.0e+00	SPATA33 U91328.21
Neuroticism	1.59	2	1	2.2	0.00	1.0e+00	AS3MT SP4
Reaction Time	1.57	3	0	0.0	0.00	1.0e+00	C2orf47 NGEF SNAP91
Hearing difficulty/problems with background noise	1.57	1	0	0.0	0.00	1.0e+00	ZNF318
Body mass index (BMI)	1.56	7	4	8.9	-0.51	2.4e-01	AS3MT BAI1 C2orf47 CTD-3074O7.5 ITIH4-AS1 MAPK3 PPP1R13B
Medication: Cholesterol lowering	1.56	1	1	2.2	0.00	1.0e+00	FES
Angina	1.55	1	1	2.2	0.00	1.0e+00	FES
Medication: Atenolol	1.55	1	1	2.2	0.00	1.0e+00	FES
Angina (self-reported)	1.55	1	1	2.2	0.00	1.0e+00	FES
Mean time to correctly identify matches	1.53	1	0	0.0	0.00	1.0e+00	SNAP91
Arm fat mass (left)	1.53	6	2	4.4	-0.74	9.3e-02	AS3MT BAI1 C2orf47 MAPK3 PPP1R13B RFWD3
Trunk fat mass	1.52	7	3	6.7	-0.78	4.0e-02	AC103965.1 AS3MT C2orf47 EFHD1 MAPK3 RFWD3 TRIM38
Age when periods started (menarche)	1.51	2	1	2.2	0.00	1.0e+00	MAPK3 ST3GAL3
Forced expiratory volume in 1-second (FEV1)	1.51	5	4	8.9	-0.18	7.7e-01	AC103965.1 CEP170 CHRNA5 PLEKHO1 U91328.21
Allergy	1.50	5	2	4.4	-0.61	2.8e-01	ANKRD44 CDK2AP1 CTD-3074O7.5 FES HSPD1
Whole body fat mass	1.50	5	3	6.7	-0.94	1.6e-02	AC103965.1 AS3MT C2orf47 MAPK3 RFWD3
Father's age at death	1.49	2	2	4.4	0.00	1.0e+00	CHRNA5 FES
Overall health rating	1.49	1	0	0.0	0.00	1.0e+00	CGREF1
Basal cell carcinoma (self-reported)	1.49	1	1	2.2	0.00	1.0e+00	SPATA33
Pulse rate, automated reading	1.48	3	2	4.4	0.00	1.0e+00	EFHD1 ITIH4-AS1 RP11-53O19.3
Blood Red Count	1.47	13	9	20.0	0.30	3.2e-01	ANKRD44 C2orf47 C6orf108 CDK2AP1 CTD-3074O7.5 DUS2 ITIH4-AS1 LL22NC03-86G7.1 LPAR2 MAPK3 SDAD1P1 ST3GAL3 SUGP2
Leg fat mass (left)	1.47	6	2	4.4	-0.93	7.6e-03	AC103965.1 AS3MT C2orf47 MAPK3 RFWD3 TRIM38
Medication: Aspirin	1.46	1	1	2.2	0.00	1.0e+00	FES
Sensitivity / hurt feelings	1.45	2	1	2.2	0.00	1.0e+00	FES SUGP2
Arm fat mass (right)	1.45	5	1	2.2	-0.71	1.8e-01	AS3MT C2orf47 MAPK3 PPP1R13B RFWD3
Medication: Allopurinol	1.45	1	0	0.0	0.00	1.0e+00	PBXIP1
Medication: Amlodipine	1.44	1	1	2.2	0.00	1.0e+00	FES
Leg fat mass (right)	1.43	4	2	4.4	-0.92	8.0e-02	AC103965.1 AS3MT MAPK3 RFWD3
Miserableness	1.43	1	0	0.0	0.00	1.0e+00	CEP170
Height	1.42	25	17	37.8	0.01	9.6e-01	AC103965.1 AS3MT CDK2AP1 CEP170 CTD-3074O7.5 CWF19L1 DFNA5 EFHD1 FES IK ITIH4-AS1 LL22NC03-86G7.1 LMAN2L LPAR2 MAPK3 MGAT3 NGEF PPAPDC1B PPP1R13B SPATA33 ST3GAL3 STK4 SUGP2 TERF2 THOC7
Chronic bronchitis/emphysema (mother)	1.40	1	1	2.2	0.00	1.0e+00	CHRNA5
Trunk fat percentage	1.39	5	3	6.7	-0.53	3.6e-01	AC103965.1 ANKRD44 CGREF1 MAPK3 RFWD3
Average weekly champagne plus white wine intake	1.39	1	0	0.0	0.00	1.0e+00	EFHD1
Hayfever, allergic rhinitis or eczema	1.38	2	2	4.4	0.00	1.0e+00	ANKRD44 HSPD1
High cholesterol (Self-reported)	1.38	1	0	0.0	0.00	1.0e+00	CGREF1
Alcohol drinker status: Previous	1.38	1	0	0.0	0.00	1.0e+00	PPP1R13B
Pulse rate	1.37	1	0	0.0	0.00	1.0e+00	ITIH4-AS1
Forced expiratory volume in 1-second (FEV1), Best measure	1.37	6	3	6.7	-0.25	6.3e-01	AC103965.1 CEP170 CHRNA5 IK PLEKHO1 U91328.21
High blood pressure (siblings)	1.37	1	1	2.2	0.00	1.0e+00	FES
Number of operations (self-reported)	1.37	1	0	0.0	0.00	1.0e+00	ERCC8
Lung FEV1/FVC ratio	1.35	6	3	6.7	-0.57	2.4e-01	AC103965.1 CHRNA5 DUS2 GRAP ITIH4-AS1 RP11-53O19.3
Gout (self-reported)	1.35	1	0	0.0	0.00	1.0e+00	PBXIP1
Number of treatments/medications taken	1.34	1	0	0.0	0.00	1.0e+00	FES
Standing height	1.34	11	8	17.8	-0.02	9.5e-01	AC103965.1 AS3MT CDK2AP1 CTD-3074O7.5 EFHD1 IK ITIH4-AS1 LPAR2 MAPK3 NGEF TERF2
Forced expiratory volume in 1-second (FEV1), predicted	1.34	1	1	2.2	0.00	1.0e+00	AC103965.1
Medication: Bendroflumethiazide	1.34	1	1	2.2	0.00	1.0e+00	FES
Coronary Artery Disease (CAD)	1.33	1	0	0.0	0.00	1.0e+00	AS3MT
Respiratory disease	1.33	2	0	0.0	0.00	1.0e+00	ANKRD44 SPATA33
Heart attack	1.32	1	1	2.2	0.00	1.0e+00	FES
Medication for cholesterol	1.32	1	0	0.0	0.00	1.0e+00	FES
Medication: Ibuprofen (e.g. Nurofen)	1.31	1	0	0.0	0.00	1.0e+00	U91328.21
Medication: Aspirin	1.31	1	1	2.2	0.00	1.0e+00	FES
Mouth/teeth dental problems	1.30	1	0	0.0	0.00	1.0e+00	PPP1R13B
Suffer from 'nerves'	1.30	1	0	0.0	0.00	1.0e+00	AS3MT
Forced vital capacity (FVC)	1.29	8	1	2.2	-0.18	6.8e-01	AC103965.1 CEP170 CHRNA5 CUL3 IK PLEKHO1 TERF2 U91328.21
Financial difficulties in last 2 years	1.29	1	1	2.2	0.00	1.0e+00	PPP1R13B
Hearing aid user	1.29	1	0	0.0	0.00	1.0e+00	ERCC8
Heart attack/myocardial infarction (self-reported)	1.29	1	1	2.2	0.00	1.0e+00	FES
Ovarian Cancer	1.28	1	0	0.0	0.00	1.0e+00	DUS2
Hand grip strength (left)	1.28	4	0	0.0	0.14	8.6e-01	AS3MT FES MAPK3 SNAP91
Body fat percentage	1.28	5	3	6.7	-0.54	3.4e-01	AC103965.1 ANKRD44 CGREF1 MAPK3 RFWD3
Medication: Laxatives (e.g. Dulcolax, Senokot)	1.28	1	0	0.0	0.00	1.0e+00	CGREF1
Alcohol intake frequency.	1.24	5	0	0.0	0.01	9.9e-01	BAI1 CDK2AP1 CGREF1 CHRNA5 TERF2
Average weekly red wine intake	1.23	1	0	0.0	0.00	1.0e+00	CDK2AP1
Hypothyroidism (self reported)	1.22	1	0	0.0	0.00	1.0e+00	DUS2
Arm fat percentage (right)	1.20	4	1	2.2	-0.06	9.4e-01	CTD-3074O7.5 MAPK3 PPP1R13B RFWD3
Arm fat percentage (left)	1.19	5	1	2.2	-0.57	3.1e-01	ANKRD44 C2orf47 MAPK3 PPP1R13B RFWD3
Leg fat percentage (left)	1.17	3	1	2.2	0.00	1.0e+00	AC103965.1 MAPK3 RFWD3
Forced vital capacity (FVC), Best measure	1.15	6	2	4.4	-0.19	7.1e-01	AC103965.1 CEP170 CUL3 IK TERF2 U91328.21
Leg fat percentage (right)	1.14	3	1	2.2	0.00	1.0e+00	AC103965.1 MAPK3 RFWD3
Lung FVC	1.13	7	2	4.4	-0.36	4.3e-01	CHRNA5 CUL3 EFHD1 FTSJ2 IK PLEKHO1 PPAPDC1B
Relative age of first facial hair	1.13	1	1	2.2	0.00	1.0e+00	SPATA33
Illnesses of siblings	1.13	1	1	2.2	0.00	1.0e+00	FES
Blood Eosinophil Count	1.11	11	6	13.3	0.19	5.8e-01	AC103965.1 CDK2AP1 ITIH4-AS1 LMAN2L LPAR2 MAPK3 PBXIP1 PRPSAP2 SUGP2 TMEM127 XPNPEP3
Heart disease (siblings)	1.09	1	0	0.0	0.00	1.0e+00	FES
Triglycerides	1.05	1	1	2.2	0.00	1.0e+00	CGREF1
Heel T-Score	1.04	7	4	8.9	0.59	1.6e-01	CDK2AP1 CWF19L1 MAPK3 NGEF PLEKHO1 PPP1R13B TMEM127
Blood Platelet Count	0.98	10	7	15.6	0.00	9.9e-01	ANKRD44 CDK2AP1 CGREF1 DFNA5 HSPD1 ITIH4-AS1 KIAA0319 LPAR2 ST3GAL3 SUGP2
Heel bone mineral density (BMD) T-score, automated (right)	0.97	2	0	0.0	0.00	1.0e+00	KIAA0319 NGEF
Heel bone mineral density (BMD) T-score, automated (left)	0.91	1	0	0.0	0.00	1.0e+00	NGEF
HDL Cholesterol	0.86	1	1	2.2	0.00	1.0e+00	DUS2
Hair/balding pattern: Pattern 4	0.77	1	0	0.0	0.00	1.0e+00	SPATA33
Blood White Count	0.63	4	4	8.9	-1.00	4.4e-03	FES MGAT3 PPP1R13B THOC7

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Prostate	10	1.23	2.9
GTEx	Brain Cerebellum	15	0.77	2.8
GTEx	Breast Mammary Tissue	18	0.94	2.8
GTEx	Cells EBV-transformed lymphocytes	12	0.87	2.8
GTEx	Colon Transverse	17	0.85	2.8
GTEx	Pancreas	13	0.81	2.8
GTEx	Brain Cortex	7	0.69	2.7
GTEx	Breast Mammary Tissue (Male)	8	0.70	2.7
GTEx	Heart Atrial Appendage	13	0.84	2.7
GTEx	Heart Left Ventricle	9	0.61	2.7
GTEx	Liver	8	1.14	2.7
GTEx	Ovary	6	0.68	2.7
GTEx	Pituitary	11	1.00	2.7
GTEx	Spleen	19	1.38	2.7
GTEx	Testis	29	0.94	2.7
GTEx	Adipose Visceral Omentum	12	0.61	2.6
GTEx	Artery Aorta	21	0.73	2.6
GTEx	Artery Tibial	29	0.80	2.6
GTEx	Brain Hippocampus	6	1.17	2.6
GTEx	Brain Nucleus accumbens basal ganglia	6	0.71	2.6
GTEx	Breast Mammary Tissue (Female)	16	1.02	2.6
GTEx	Cells Transformed fibroblasts	34	0.83	2.6
GTEx	Colon Sigmoid	12	0.84	2.6
GTEx	Esophagus Gastroesophageal Junction	9	0.64	2.6
GTEx	Esophagus Mucosa	23	0.71	2.6
GTEx	Esophagus Muscularis	27	0.86	2.6
GTEx	Muscle Skeletal	23	0.82	2.6
GTEx	Skin Not Sun Exposed Suprapubic	15	0.62	2.6
GTEx	Skin Sun Exposed Lower leg	21	0.59	2.6
GTEx	Small Intestine Terminal Ileum	4	0.89	2.6
GTEx	Thyroid	28	0.72	2.6
GTEx	Whole Blood	16	0.83	2.6
ROSMAP	Brain Pre-frontal Cortex	33	0.77	2.6
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	9	0.57	2.6
The Cancer Genome Atlas	Esophageal Carcinoma	2	0.30	2.6
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	16	0.67	2.6
GTEx	Adipose Subcutaneous	19	0.56	2.5
GTEx	Artery Coronary	6	0.52	2.5
GTEx	Brain Caudate basal ganglia	3	0.33	2.5
GTEx	Brain Cerebellar Hemisphere	9	0.62	2.5
GTEx	Lung	19	0.68	2.5
GTEx	Nerve Tibial	24	0.57	2.5
GTEx	Stomach	9	0.64	2.5
CommonMind	Brain Pre-frontal Cortex	28	0.53	2.5
The Cancer Genome Atlas	Colon Adenocarcinoma	12	0.61	2.5
The Cancer Genome Atlas	Glioblastoma Multiforme	5	0.52	2.5
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	9	0.46	2.5
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	8	0.52	2.5
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	10	0.63	2.5
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	8	0.64	2.5
The Cancer Genome Atlas	Soft Tissue Sarcoma	6	0.59	2.5
The Cancer Genome Atlas	Stomach Adenocarcinoma	10	0.62	2.5
The Cancer Genome Atlas	Testicular Germ Cell Tumors	6	0.49	2.5
The Cancer Genome Atlas	Thyroid Carcinoma	39	0.79	2.5
GTEx	Adrenal Gland	9	0.63	2.4
GTEx	Brain Frontal Cortex BA9	2	0.22	2.4
GTEx	Brain Hypothalamus	4	0.70	2.4
GTEx	Uterus	2	0.36	2.4
GTEx	Vagina	4	0.65	2.4
The Cancer Genome Atlas	Breast Invasive Carcinoma	19	0.45	2.4
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	6	0.57	2.4
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	11	0.42	2.4
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	16	0.41	2.4
The Cancer Genome Atlas	Brain Lower Grade Glioma	16	0.39	2.4
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	6	0.56	2.4
The Cancer Genome Atlas	Lung Adenocarcinoma	11	0.39	2.4
The Cancer Genome Atlas	Prostate Adenocarcinoma	24	0.54	2.4
GTEx	Brain Putamen basal ganglia	3	0.49	2.3
METSIM	Adipose	13	0.29	2.3
NTR	Blood	12	0.50	2.3
YFS	Blood	24	0.53	2.3
The Cancer Genome Atlas	Rectum Adenocarcinoma	2	0.30	2.3
The Cancer Genome Atlas	Skin Cutaneous Melanoma	1	0.20	2.3
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	0	0.00	2.0